alefacept 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
lymphocyte function-associated antigen 3 receptors 5088 222535-22-0

Description:

MoleculeDescription

Synonyms:

  • alefacept
  • BG9712
  • LFA3TIP
  • BG9273
  • amevive
A recombinant human fusion protein of LFA-3 antigen and immunoglobulin IGG1 that binds to CD2 ANTIGENS on memory T-LYMPHOCYTES, preventing their activation and proliferation. It is used in the management of moderate to severe chronic plaque PSORIASIS.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Jan. 30, 2003 FDA ASTELLAS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Carotid artery thrombosis 653.06 510.61 154 8097 8938 90611258
Neurologic neglect syndrome 651.98 510.61 153 8098 8694 90611502
Adjustment disorder 638.88 510.61 153 8098 9489 90610707
Personality disorder 600.10 510.61 153 8098 12291 90607905
Skin haemorrhage 557.80 510.61 162 8089 21218 90598978
Hemiplegia 555.80 510.61 152 8099 16008 90604188
Affect lability 548.15 510.61 154 8097 17909 90602287
Sensory loss 543.49 510.61 153 8098 17922 90602274
Motor dysfunction 534.12 510.61 153 8098 19077 90601119
Gangrene 531.93 510.61 140 8111 12736 90607460
Arterial occlusive disease 531.81 510.61 139 8112 12307 90607889
Coordination abnormal 522.65 510.61 154 8097 21202 90598994
Sinus congestion 518.01 510.61 162 8089 27262 90592934
Respiratory tract congestion 513.90 510.61 161 8090 27249 90592947

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neurologic neglect syndrome 682.70 505.15 155 8249 9143 110571752
Carotid artery thrombosis 682.53 505.15 156 8248 9482 110571413
Adjustment disorder 659.67 505.15 155 8249 10640 110570255
Personality disorder 632.97 505.15 155 8249 12682 110568213
Affect lability 580.33 505.15 156 8248 18481 110562414
Skin haemorrhage 571.73 505.15 164 8240 24663 110556232
Sensory loss 553.99 505.15 155 8249 21302 110559593
Hemiplegia 540.29 505.15 154 8250 22628 110558267
Sinus congestion 538.62 505.15 164 8240 30295 110550600
Arterial occlusive disease 537.78 505.15 141 8263 15167 110565728
Sneezing 534.96 505.15 165 8239 31819 110549076
Motor dysfunction 534.24 505.15 155 8249 24251 110556644
Coordination abnormal 533.59 505.15 156 8248 25072 110555823
Gangrene 533.40 505.15 142 8262 16199 110564696
Respiratory tract congestion 532.26 505.15 163 8241 30694 110550201
Sinus disorder 527.01 505.15 164 8240 32564 110548331

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L04AA15 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSUPPRESSANTS
IMMUNOSUPPRESSANTS
Selective immunosuppressants
FDA CS M0018640 Recombinant Fusion Proteins
FDA CS M0028142 Immunoconjugates
MeSH PA D003879 Dermatologic Agents
MeSH PA D007155 Immunologic Factors
FDA MoA N0000175857 CD2-directed Antibody Interactions
FDA EPC N0000175859 CD2-directed LFA-3/Fc Fusion Protein
CHEBI has role CHEBI:35526 hypoglycemic agent
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:50748 antipsoriatic
CHEBI has role CHEBI:75835 anti-anaemic agent

Related Drugs by ATC class:

L04AA Selective immunosuppressants 10 drugs
abataceptapremilastbelataceptbelumosudilcladribinegusperimusimlifidasemycophenolic acidnerandomilastremibrutinib

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Plaque psoriasis indication 200965009




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
T-cell surface antigen CD2 Surface antigen INHIBITOR DRUG LABEL DRUG LABEL

External reference:

IDSource
ELK3V90G6C UNII
D02800 KEGG_DRUG
4021373 VANDF
C0962603 UMLSCUI
CHEBI:749492 CHEBI
CHEMBL1201571 ChEMBL_ID
DB00092 DRUGBANK_ID
D000077944 MESH_DESCRIPTOR_UI
8059 INN_ID
6787 IUPHAR_LIGAND_ID
299635 RXNORM
17114 MMSL
46117 MMSL
d04843 MMSL
009880 NDDF
398691006 SNOMEDCT_US
398857009 SNOMEDCT_US

Pharmaceutical products:

None